Using Nafamostat for better ECMO management
A Novel Strategy Combined Regional Anticoagulation in Membrane Oxygenator and Low-intensity of Systemic Anticoagulation Applied in Management of Extracorporeal Membrane Oxygenation
This study is testing if using Nafamostat with a lower dose of blood thinners can help improve safety and outcomes for adults on ECMO due to severe breathing problems.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 60 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Beijing Chao Yang Hospital Academic / other |
| Locations | 1 site (Beijing, Beijing Municipality) |
| Trial ID | NCT06676085 on ClinicalTrials.gov |
What this trial studies
This study investigates a new approach to managing anticoagulation in patients on ECMO, focusing on the use of Nafamostat combined with low-intensity systemic anticoagulation. ECMO is a life-support technique for patients with severe respiratory or circulatory failure, but it carries a high risk of bleeding and thrombotic events. By optimizing anticoagulation strategies, the study aims to reduce these risks and improve patient outcomes. The trial will include adult patients who have received ECMO due to severe respiratory failure.
Who should consider this trial
Good fit: Ideal candidates are adults over 18 years old who are receiving ECMO for severe respiratory failure.
Not a fit: Patients with contraindications to anticoagulants, severe hypertension, or those who are pregnant or breastfeeding may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly reduce the incidence of bleeding and thrombotic events in ECMO patients, potentially improving survival rates.
How similar studies have performed: While there is ongoing research in ECMO management, this specific approach using Nafamostat is novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * age older than 18 years old * received ECMO because of severe respiratory failure Exclusion Criteria: * anticoagulant contraindications * cerebral infarction or suspected patients * severe hypertension * women in gestational and lactational period * hemophilia * allergic to heparin or Nafamostat * unwilling or unable to complete the study
Where this trial is running
Beijing, Beijing Municipality
- Bing Sun — Beijing, Beijing Municipality, China (Recruiting)
Study contacts
- Principal investigator: Bing Sun, MD — Beijing Chao Yang Hospital
- Study coordinator: Bing Sun, MD
- Email: ricusunbing@126.com
- Phone: +8613911151075
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.